Sofosbuvir plus ribavirin is tolerable and effective even in elderly patients 75-years-old and over.

CONCLUSION: Although ribavirin dose reduction or interruption was required with advanced age, sofosbuvir plus ribavirin appears tolerable and highly effective even in patients ≥ 75-years-old. PMID: 33033572 [PubMed]

https://www.ncbi.nlm.nih.gov/pubmed/33033572?dopt=Abstract

Source: World Journal of Hepatology - October 10, 2020 Category: Gastroenterology Tags: World J Hepatol Source Type: research